{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:52:38Z","timestamp":1791809558568,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7244288"],"award-info":[{"award-number":["7244288"]}]},{"name":"Capital Institute of Pediatrics basic special key funding project","award":["JCYJ-2025-11"],"award-info":[{"award-number":["JCYJ-2025-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genomics"],"DOI":"10.1186\/s12864-025-11377-4","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:35:07Z","timestamp":1740400507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["M6A methyltransferase METTL3 promotes glucose metabolism hub gene expression and induces metabolic dysfunction-associated steatotic liver disease (MASLD)"],"prefix":"10.1186","volume":"26","author":[{"given":"Shuowen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"11377_CR1","doi-asserted-by":"publisher","first-page":"100261","DOI":"10.1016\/j.jhepr.2021.100261","volume":"3","author":"OT Ayonrinde","year":"2021","unstructured":"Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - reconciling the present with the past. JHEP Rep. 2021;3:100261. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100261","journal-title":"JHEP Rep"},{"key":"11377_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"11377_CR3","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021","journal-title":"J Hepatol"},{"key":"11377_CR4","doi-asserted-by":"publisher","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;771797\u2013835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","DOI":"10.1097\/HEP.0000000000000323"},{"key":"11377_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DMSO.S146339","volume":"11","author":"R Sarwar","year":"2018","unstructured":"Sarwar R, Pierce N, Koppe S. Obesity and nonalcoholic fatty liver disease: current perspectives. Diabetes Metab Syndr Obes. 2018;11:533\u201342. https:\/\/doi.org\/10.2147\/DMSO.S146339","journal-title":"Diabetes Metab Syndr Obes"},{"key":"11377_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17:81\u201392. https:\/\/doi.org\/10.1038\/s41575-019-0210-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"11377_CR7","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1038\/s41598-021-84577-z","volume":"11","author":"M Zhai","year":"2021","unstructured":"Zhai M, Liu Z, Long J, Zhou Q, Yang L, Zhou Q, et al. The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017. Sci Rep. 2021;11:5195. https:\/\/doi.org\/10.1038\/s41598-021-84577-z","journal-title":"Sci Rep"},{"key":"11377_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cld.2015.10.003","volume":"20","author":"NP Goyal","year":"2016","unstructured":"Goyal NP, Schwimmer JB. The progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20:325\u201338. https:\/\/doi.org\/10.1016\/j.cld.2015.10.003","journal-title":"Clin Liver Dis"},{"key":"11377_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.pcl.2021.07.013","volume":"68","author":"T Mitsinikos","year":"2021","unstructured":"Mitsinikos T, Mrowczynski-Hernandez P, Kohli R. Pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am. 2021;68:1309\u201320. https:\/\/doi.org\/10.1016\/j.pcl.2021.07.013","journal-title":"Pediatr Clin North Am"},{"key":"11377_CR10","doi-asserted-by":"publisher","unstructured":"Jobira B, Frank DN, Silveira LJ, Pyle L, Kelsey MM, Garcia-Reyes Y, et al. Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome. PLoS ONE. 2021;16e0245219. https:\/\/doi.org\/10.1371\/journal.pone.0245219","DOI":"10.1371\/journal.pone.0245219"},{"key":"11377_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/jclinpath-2022-208246","volume":"75","author":"C Wang","year":"2022","unstructured":"Wang C, Pai AK, Putra J. Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. J Clin Pathol. 2022;75:443\u201351. https:\/\/doi.org\/10.1136\/jclinpath-2022-208246","journal-title":"J Clin Pathol"},{"key":"11377_CR12","doi-asserted-by":"publisher","unstructured":"Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology. 2022;76:429\u201344. https:\/\/doi.org\/10.1002\/hep.32403","DOI":"10.1002\/hep.32403"},{"key":"11377_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","volume":"68","author":"R Younes","year":"2018","unstructured":"Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018;68:326\u201334. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.006","journal-title":"J Hepatol"},{"key":"11377_CR14","doi-asserted-by":"publisher","first-page":"100142","DOI":"10.1016\/j.jhepr.2020.100142","volume":"2","author":"J O\u2019Hara","year":"2020","unstructured":"O\u2019Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study. JHEP Rep. 2020;2:100142. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100142","journal-title":"JHEP Rep"},{"key":"11377_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hep.31220","volume":"73","author":"B Zhou","year":"2021","unstructured":"Zhou B, Liu C, Xu L, Yuan Y, Zhao J, Zhao W, et al. N(6) -methyladenosine reader protein YT521-B homology domain-containing 2 suppresses liver steatosis by regulation of mRNA stability of lipogenic genes. Hepatology. 2021;73:91\u2013103. https:\/\/doi.org\/10.1002\/hep.31220","journal-title":"Hepatology"},{"key":"11377_CR16","doi-asserted-by":"publisher","unstructured":"Li Z, Qi J, Liu H, Tang Y, Liu J, Sun C. Abnormal m6A modification in non-alcoholic fatty liver disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021:46785\u201392. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2021.210264","DOI":"10.11817\/j.issn.1672-7347.2021.210264"},{"key":"11377_CR17","doi-asserted-by":"publisher","first-page":"780617","DOI":"10.3389\/fendo.2021.780617","volume":"12","author":"Y Luo","year":"2021","unstructured":"Luo Y, Zhang Z, Xiang L, Zhou B, Wang X, Lin Y, et al. Analysis of N6-methyladenosine methylation modification in fructose-induced non-alcoholic fatty liver disease. Front Endocrinol (Lausanne). 2021;12:780617. https:\/\/doi.org\/10.3389\/fendo.2021.780617","journal-title":"Front Endocrinol (Lausanne)"},{"key":"11377_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2217\/epi-2019-0009","volume":"11","author":"Z Luo","year":"2019","unstructured":"Luo Z, Zhang Z, Tai L, Zhang L, Sun Z, Zhou L. Comprehensive analysis of differences of N(6)-methyladenosine RNA methylomes between high-fat-fed and normal mouse livers. Epigenomics. 2019;11:1267\u201382. https:\/\/doi.org\/10.2217\/epi-2019-0009","journal-title":"Epigenomics"},{"key":"11377_CR19","doi-asserted-by":"publisher","first-page":"973116","DOI":"10.3389\/fphar.2022.973116","volume":"13","author":"W Cheng","year":"2022","unstructured":"Cheng W, Li M, Zhang L, Zhou C, Yu S, Peng X, et al. New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC. Front Pharmacol. 2022;13:973116. https:\/\/doi.org\/10.3389\/fphar.2022.973116","journal-title":"Front Pharmacol"},{"key":"11377_CR20","doi-asserted-by":"publisher","first-page":"116526","DOI":"10.1016\/j.ejmech.2024.116526","volume":"274","author":"NJ Harrahill","year":"2024","unstructured":"Harrahill NJ, Hadden MK. Small molecules that regulate the N(6)-methyladenosine RNA modification as potential anti-cancer agents. Eur J Med Chem. 2024;274:116526. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116526","journal-title":"Eur J Med Chem"},{"key":"11377_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.omto.2021.05.003","volume":"22","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Chen W, Zheng X, Guo Y, Cao J, Zhang Y, et al. Regulatory role and mechanism of m(6)A RNA modification in human metabolic diseases. Mol Ther Oncolytics. 2021;22:52\u201363. https:\/\/doi.org\/10.1016\/j.omto.2021.05.003","journal-title":"Mol Ther Oncolytics"},{"key":"11377_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10:93\u20135. https:\/\/doi.org\/10.1038\/nchembio.1432","journal-title":"Nat Chem Biol"},{"key":"11377_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1101\/gad.309146.117","volume":"32","author":"P Knuckles","year":"2018","unstructured":"Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N, Carl SH, et al. Zc3h13\/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15\/Spenito to the m(6)A machinery component Wtap\/Fl(2)d. Genes Dev. 2018;32:415\u201329. https:\/\/doi.org\/10.1101\/gad.309146.117","journal-title":"Genes Dev"},{"key":"11377_CR24","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1038\/s41467-021-23892-5","volume":"12","author":"P Bawankar","year":"2021","unstructured":"Bawankar P, Lence T, Paolantoni C, Haussmann IU, Kazlauskiene M, Jacob D, et al. Hakai is required for stabilization of core components of the m(6)A mRNA methylation machinery. Nat Commun. 2021;12:3778. https:\/\/doi.org\/10.1038\/s41467-021-23892-5","journal-title":"Nat Commun"},{"key":"11377_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","volume":"63","author":"P Wang","year":"2016","unstructured":"Wang P, Doxtader KA, Nam Y. Structural basis for cooperative function of METTL3 and Mettl14 methyltransferases. Mol Cell. 2016;63:306\u201317. https:\/\/doi.org\/10.1016\/j.molcel.2016.05.041","journal-title":"Mol Cell"},{"key":"11377_CR26","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.ymthe.2021.09.016","volume":"30","author":"Z Peng","year":"2022","unstructured":"Peng Z, Gong Y, Wang X, He W, Wu L, Zhang L, et al. METTL3-m(6)A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. Mol Ther. 2022;30:932\u201346. https:\/\/doi.org\/10.1016\/j.ymthe.2021.09.016","journal-title":"Mol Ther"},{"key":"11377_CR27","doi-asserted-by":"publisher","first-page":"109968","DOI":"10.1016\/j.celrep.2021.109968","volume":"37","author":"Y Qin","year":"2021","unstructured":"Qin Y, Li B, Arumugam S, Lu Q, Mankash SM, Li J, et al. m(6)A mRNA methylation-directed myeloid cell activation controls progression of NAFLD and obesity. Cell Rep. 2021;37:109968. https:\/\/doi.org\/10.1016\/j.celrep.2021.109968","journal-title":"Cell Rep"},{"key":"11377_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbrc.2019.08.018","volume":"518","author":"W Xie","year":"2019","unstructured":"Xie W, Ma LL, Xu YQ, Wang BH, Li SM. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys Res Commun. 2019;518:120\u20136. https:\/\/doi.org\/10.1016\/j.bbrc.2019.08.018","journal-title":"Biochem Biophys Res Commun"},{"key":"11377_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.celrep.2018.10.068","volume":"25","author":"X Zhong","year":"2018","unstructured":"Zhong X, Yu J, Frazier K, Weng X, Li Y, Cham CM, et al. Circadian clock regulation of hepatic lipid metabolism by modulation of m(6)A mRNA methylation. Cell Rep. 2018;25:1816\u201328. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.068","journal-title":"Cell Rep"},{"key":"11377_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.gpb.2020.06.003","volume":"18","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang Q, Cui G, Zhao F, Tian X, Sun BF, et al. m(6)A regulates liver metabolic disorders and hepatogenous diabetes. Genomics Proteom Bioinf. 2020;18:371\u201383. https:\/\/doi.org\/10.1016\/j.gpb.2020.06.003","journal-title":"Genomics Proteom Bioinf"},{"key":"11377_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","volume":"17","author":"D Ferguson","year":"2021","unstructured":"Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021;17:484\u201395. https:\/\/doi.org\/10.1038\/s41574-021-00507-z","journal-title":"Nat Rev Endocrinol"},{"key":"11377_CR32","doi-asserted-by":"publisher","first-page":"100815","DOI":"10.1016\/j.jhepr.2023.100815","volume":"5","author":"A De Masi","year":"2023","unstructured":"De Masi A, Li X, Lee D, Jeon J, Wang Q, Baek S, et al. Cyclo(His-Pro): A further step in the management of steatohepatitis. JHEP Rep. 2023;5:100815. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100815","journal-title":"JHEP Rep"},{"key":"11377_CR33","doi-asserted-by":"publisher","first-page":"111303","DOI":"10.1016\/j.cellsig.2024.111303","volume":"121","author":"S Wang","year":"2024","unstructured":"Wang S, Zhang W, Wang Z, Liu Z, Yi X, Wu J. METTL3-m6A-YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease. Cell Signal. 2024;121:111303. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111303","journal-title":"Cell Signal"},{"key":"11377_CR34","doi-asserted-by":"publisher","first-page":"1403587","DOI":"10.3389\/fgene.2024.1403587","volume":"15","author":"S Wang","year":"2024","unstructured":"Wang S, Wang Z, Liu Z, Wu J. Prognostic value of four immune-related genes in lower-grade gliomas: a biomarker discovery study. Front Genet. 2024;15:1403587. https:\/\/doi.org\/10.3389\/fgene.2024.1403587","journal-title":"Front Genet"},{"key":"11377_CR35","doi-asserted-by":"publisher","first-page":"1199902","DOI":"10.3389\/fcell.2023.1199902","volume":"11","author":"Z Lu","year":"2023","unstructured":"Lu Z, Qian P, Chang J, He X, Zhang H, Wu J, et al. Multi-omics analysis explores the effect of chronic exercise on liver metabolic reprogramming in mice. Front Cell Dev Biol. 2023;11:1199902. https:\/\/doi.org\/10.3389\/fcell.2023.1199902","journal-title":"Front Cell Dev Biol"},{"key":"11377_CR36","doi-asserted-by":"publisher","first-page":"1023482","DOI":"10.3389\/fnmol.2022.1023482","volume":"15","author":"P Qian","year":"2022","unstructured":"Qian P, Ma F, Zhang W, Cao D, Li L, Liu Z, et al. Chronic exercise remodels the lysine acetylome in the mouse hippocampus. Front Mol Neurosci. 2022;15:1023482. https:\/\/doi.org\/10.3389\/fnmol.2022.1023482","journal-title":"Front Mol Neurosci"},{"key":"11377_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41568-020-0253-2","volume":"20","author":"I Barbieri","year":"2020","unstructured":"Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer. 2020;20:303\u201322. https:\/\/doi.org\/10.1038\/s41568-020-0253-2","journal-title":"Nat Rev Cancer"},{"key":"11377_CR38","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616\u201324. https:\/\/doi.org\/10.1038\/s41422-018-0040-8","journal-title":"Cell Res"},{"key":"11377_CR39","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1186\/s12889-024-20161-0","volume":"24","author":"J Zhou","year":"2024","unstructured":"Zhou J, Han J. Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National health and nutrition examination survey. BMC Public Health. 2024;24:2742. https:\/\/doi.org\/10.1186\/s12889-024-20161-0","journal-title":"BMC Public Health"},{"key":"11377_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01184-8","author":"L Peng","year":"2025","unstructured":"Peng L, Xiang S, Wang T, Yang M, Duan Y, Ma X, et al. The hepatic clock synergizes with HIF-1alpha to regulate nucleotide availability during liver damage repair. Nat Metab. 2025. https:\/\/doi.org\/10.1038\/s42255-024-01184-8","journal-title":"Nat Metab"},{"key":"11377_CR41","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.tjnut.2024.03.007","volume":"154","author":"AB Santamarina","year":"2024","unstructured":"Santamarina AB, Sertorio MN, Mennitti LV, Souza EA, Souza DV, Ribeiro DA, et al. Hepatic effects of low-carbohydrate diet associated with different lipid sources: insights into oxidative stress, cytotoxicity, and epigenetic markers in a mouse model of obesity. J Nutr. 2024;154:1517\u201331. https:\/\/doi.org\/10.1016\/j.tjnut.2024.03.007","journal-title":"J Nutr"},{"key":"11377_CR42","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s42255-023-00801-2","volume":"5","author":"JM Weiss","year":"2023","unstructured":"Weiss JM, Palmieri EM, Gonzalez-Cotto M, Bettencourt IA, Megill EL, Snyder NW, et al. Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice. Nat Metab. 2023;5:981\u201395. https:\/\/doi.org\/10.1038\/s42255-023-00801-2","journal-title":"Nat Metab"},{"key":"11377_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","volume":"7","author":"Y Duan","year":"2022","unstructured":"Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7:265. https:\/\/doi.org\/10.1038\/s41392-022-01125-5","journal-title":"Signal Transduct Target Ther"},{"key":"11377_CR44","doi-asserted-by":"publisher","first-page":"6000","DOI":"10.1038\/s41467-021-26209-8","volume":"12","author":"Y Lai","year":"2021","unstructured":"Lai Y, Liu CW, Yang Y, Hsiao YC, Ru H, Lu K. High-coverage metabolomics uncovers microbiota-driven biochemical landscape of interorgan transport and gut-brain communication in mice. Nat Commun. 2021;12:6000. https:\/\/doi.org\/10.1038\/s41467-021-26209-8","journal-title":"Nat Commun"},{"key":"11377_CR45","doi-asserted-by":"publisher","unstructured":"Mu C, Wang S, Wang Z, Tan J, Yin H, Wang Y, et al. Mechanisms and therapeutic targets of mitochondria in the progression of metabolic dysfunction-associated steatotic liver disease. Ann Hepatol. 2024;101774. https:\/\/doi.org\/10.1016\/j.aohep.2024.101774","DOI":"10.1016\/j.aohep.2024.101774"},{"key":"11377_CR46","doi-asserted-by":"publisher","unstructured":"Sanders FW, Griffin JL. De Novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016:91452\u201368. https:\/\/doi.org\/10.1111\/brv.12178","DOI":"10.1111\/brv.12178"},{"key":"11377_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138920106779116928","volume":"7","author":"R Lupu","year":"2006","unstructured":"Lupu R, Menendez JA. Pharmacological inhibitors of fatty acid synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol. 2006;7:483\u201393. https:\/\/doi.org\/10.2174\/138920106779116928","journal-title":"Curr Pharm Biotechnol"},{"key":"11377_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pharmthera.2017.02.021","volume":"177","author":"D Buckley","year":"2017","unstructured":"Buckley D, Duke G, Heuer TS, O\u2019Farrell M, Wagman AS, McCulloch W, et al. Fatty acid synthase - modern tumor cell biology insights into a classical oncology target. Pharmacol Ther. 2017;177:23\u201331. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.021","journal-title":"Pharmacol Ther"},{"key":"11377_CR49","doi-asserted-by":"publisher","unstructured":"Comajoan P, Gubern C, Huguet G, Serena J, Kadar E, Castellanos M. Evaluation of common housekeeping proteins under ischemic conditions and\/or rt-PA treatment in bEnd.3 cells. J Proteom. 2018:18410\u20135. https:\/\/doi.org\/10.1016\/j.jprot.2018.06.011","DOI":"10.1016\/j.jprot.2018.06.011"},{"key":"11377_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/elps.201500385","volume":"37","author":"K Goasdoue","year":"2016","unstructured":"Goasdoue K, Awabdy D, Bjorkman ST, Miller S. Standard loading controls are not reliable for Western blot quantification across brain development or in pathological conditions. Electrophoresis. 2016;37:630\u20134. https:\/\/doi.org\/10.1002\/elps.201500385","journal-title":"Electrophoresis"},{"key":"11377_CR51","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1038\/s41467-022-34095-x","volume":"13","author":"E Haythorne","year":"2022","unstructured":"Haythorne E, Lloyd M, Walsby-Tickle J, Tarasov AI, Sandbrink J, Portillo I, et al. Altered glycolysis triggers impaired mitochondrial metabolism and mTORC1 activation in diabetic beta-cells. Nat Commun. 2022;13:6754. https:\/\/doi.org\/10.1038\/s41467-022-34095-x","journal-title":"Nat Commun"},{"key":"11377_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijbiomac.2019.01.064","volume":"127","author":"P Semenyuk","year":"2019","unstructured":"Semenyuk P, Barinova K, Muronetz V. Glycation of alpha-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase. Int J Biol Macromol. 2019;127:278\u201385. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.01.064","journal-title":"Int J Biol Macromol"},{"key":"11377_CR53","doi-asserted-by":"publisher","unstructured":"Shestov AA, Liu X, Ser Z, Cluntun AA, Hung YP, Huang L, et al. Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. Elife. 2014;3. https:\/\/doi.org\/10.7554\/eLife.03342","DOI":"10.7554\/eLife.03342"},{"key":"11377_CR54","doi-asserted-by":"publisher","first-page":"130232","DOI":"10.1098\/rsob.130232","volume":"4","author":"NM Gruning","year":"2014","unstructured":"Gruning NM, Du D, Keller MA, Luisi BF, Ralser M. Inhibition of triosephosphate isomerase by phosphoenolpyruvate in the feedback-regulation of glycolysis. Open Biol. 2014;4:130232. https:\/\/doi.org\/10.1098\/rsob.130232","journal-title":"Open Biol"},{"key":"11377_CR55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ejmg.2017.03.008","volume":"60","author":"C Oliver","year":"2017","unstructured":"Oliver C, Timson DJ. In silico prediction of the effects of mutations in the human triose phosphate isomerase gene: towards a predictive framework for TPI deficiency. Eur J Med Genet. 2017;60:289\u201398. https:\/\/doi.org\/10.1016\/j.ejmg.2017.03.008","journal-title":"Eur J Med Genet"},{"key":"11377_CR56","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.bbrc.2016.11.156","volume":"482","author":"H Jiang","year":"2017","unstructured":"Jiang H, Ma N, Shang Y, Zhou W, Chen T, Guan D, et al. Triosephosphate isomerase 1 suppresses growth, migration and invasion of hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2017;482:1048\u201353. https:\/\/doi.org\/10.1016\/j.bbrc.2016.11.156","journal-title":"Biochem Biophys Res Commun"},{"key":"11377_CR57","doi-asserted-by":"publisher","unstructured":"Pekel G, Ari F. Therapeutic targeting of cancer metabolism with triosephosphate isomerase. Chem Biodivers. 2020;17e2000012. https:\/\/doi.org\/10.1002\/cbdv.202000012","DOI":"10.1002\/cbdv.202000012"}],"container-title":["BMC Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-025-11377-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12864-025-11377-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12864-025-11377-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:35:14Z","timestamp":1740400514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenomics.biomedcentral.com\/articles\/10.1186\/s12864-025-11377-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11377"],"URL":"https:\/\/doi.org\/10.1186\/s12864-025-11377-4","relation":{},"ISSN":["1471-2164"],"issn-type":[{"value":"1471-2164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by The Ethics Committee on Animal Care and Use of the Capital Institute of Pediatrics (SHERLL2021032).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}